Fate Therapeutics

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

movers image

$BTC

ACHR

AMBA

ARWR

BTBT

FATE

IREN

MNSO

MRNO

URBN

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.

Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday

Charles Schwab shutter

News

Intraday Update

Markets

Movers

Trading Ideas

AEON

AMIX

ANGO

ARVN

ATGL

CGBS

CHGG

CMND

EGHT

EOSE

FNKO

GRNQ

GROM

KOSS

LCFY

MTCH

NAAS

NEGG

NTWK

PACB

RDDT

SANA

SCHW

SFBS

SHOP

SHPW

SILO

SPRC

TKLF

VRPX

ZENV

Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Konskie,,Poland,-,January,05,,2019:,Unitedhealth,Group,Logo,Displayed

JANX

NVAX

UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America  And Other Big Stocks Moving Higher On Tuesday

Fate Therapeutics Inc

Earnings

Press Releases

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Health Care

Fate Therapeutics to Present at Upcoming December Investor Conferences

Management

Fate Therapeutics Announces Leadership Transition

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

General

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics to Present at Upcoming Investor Conferences

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Biomea Fusion

Coherus BioSciences

Cellectis S.A. - American Depositary Shares

Cellectis

Coya Therapeutics

Caribou Biosciences

Elutia

Immunic

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Seres Therapeutics

Nkarta

PepGen

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Sutro Biopharma

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

TScan Therapeutics

Instil Bio

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

2seventy bio

Vor Biopharma

Vaxart

XBiotech

HC Wainwright & Co.

Piper Sandler

Canaccord Genuity

BMO Capital

Wedbush

Comments

Fate Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga